Program Book - Confex

ACR/ARHP Poster Session C
286
2196. Safety of Rituximab in Combination with Other Biologic
Disease-Modifying Antirheumatic Drugs in Rheumatoid
Arthritis: 48-Week Data From SUNDIAL. William Rigby 1 ,
Philip J. Mease 2 , Ewa Olech 3 , Mark Ashby 4 and Swati
Tole 4 , 1 Dartmouth Medical School, Lebanon, NH, 2 Swedish
Medical Center, Seattle, WA, 3 Oklahoma Medical Research
Foundation, Oklahoma City, OK, 4 Genentech, Inc., South San
Francisco, CA
2197. Switching of Biologic Disease-Modifying Antirheumatic
Drugs During the First Year in Patients with Rheumatoid
Arthritis in a Real-World Setting. Brian Meissner, Digisha
Trivedi, Min You and Tony Hebden, Bristol-Myers Squibb,
Plainsboro, NJ
2198. Real-World Switching Patterns in RA Patients Receiving
Abatacept, Adalimumab, Etanercept or Infliximab As
Second-Line Biologic Therapy. Brian Meissner, Lisa
Rosenblatt, Digisha Trivedi, Min You and Tony Hebden,
Bristol-Myers Squibb, Plainsboro, NJ
2199. Long-Term Safety of Rituximab in Rheumatoid Arthritis:
Pooled Analysis of Patients in Clinical Trials with up to
9.5 Years of Treatment. Ronald F. van Vollenhoven 1 , Paul
Emery 2 , Clifton O. Bingham 3 , Edward Keystone 4 , Roy M.
Fleischmann 5 , Daniel E. Furst 6 , Nicola Tyson 7 , Neil Collinson 7
and Patricia B. Lehane 7 , 1 The Karolinska Institute, Stockholm,
Sweden, 2 Leeds Institute of Molecular Medicine, University
of Leeds and NIHR Leeds Musculoskeletal Biomedical
Research Unit, Leeds, UK, Leeds, United Kingdom, 3 Johns
Hopkins University, Baltimore, MD, 4 University of Toronto,
Toronto, ON, 5 University of Texas, Dallas, TX, 6 UCLA, Los
Angeles, CA, 7 Roche Products Limited, Welwyn Garden City,
United Kingdom
2200. Eight Year Results of Disease Activity Steered Treatment in
a Large Recent Rheumatoid Arthritis Cohort: Clinical and
Radiological Outcomes. Linda Dirven 1 , M. van den Broek 1 ,
N.B. Klarenbeek 1 , K.H. Han 2 , H.K Ronday 3 , P.J.S.M. Kerstens 4 ,
Tom W.J. Huizinga 1 , Willem F. Lems 5 and C.F. Allaart 1 , 1 Leiden
University Medical Center, Leiden, Netherlands, 2 Maasstad
Hospital, Rotterdam, Netherlands, 3 Haga Hospital, The Hague,
Netherlands, 4 Jan van Breemen Research Institute | Reade,
Amsterdam, Netherlands, 5 VU University medical center,
Amsterdam, Netherlands
2201. A Phase I, Randomized, Double-Blind, Placebo-Controlled,
Single-Dose, Dose Escalation Study to Evaluate the Safety,
Tolerability and Pharmacokinetics of BIIB023 (Anti-TWEAK)
in Subjects with Rheumatoid Arthritis. Nicolas Wisniacki 1 ,
Vishala L. Chindalore 2 , Christine E. Codding 3 , Maria W.
Greenwald 4 , Marianne L. Shaw 5 , Sergey Fitilev 6 , Olga Ershova 7 ,
Xiao Hu 8 , Timothy S. Zheng 9 , Lakshmi Amaravadi 8 , Ray Zhang 9
and Linda C. Burkly 8 , 1 Biogen Idec, Maidenhead, United
Kingdom, 2 Anniston Medical Clinic PC, Anniston, AL, 3 Health
Research of Oklahoma, Oklahoma City, OK, 4 Desert Medical
Advances, Palm Desert, CA, 5 Duncansville, PA, 6 M. Sechenov
Moscow Medical Academy, Moscow, Russia, 7 Clinical
Hospital for Emergency Care, Moscow, Russia, 8 Biogen Idec,
Cambridge, MA, 9 Biogen Idec Inc, Cambridge, MA
2011 Program Book
2202. Response to Second-Line DMARDs and TNFi in Seropositive
and Seronegative Patients in Early and Late Rheumatoid
Arthritis Are Not the Same: Results From the CATCH Cohort
and a Large, Established Rheumatoid Arthritis Database.
Yang Cao 1 , Ashley Bonner 2 , Lillian J. Barra 3 , J. Carter Thorne 4 ,
Boulos Haraoui 5 , Gilles Boire 6 , Carol A. Hitchon 7 , Nicole G.
H. Le Riche 8 , Andrew E. Thompson 9 , Edward Keystone 10 ,
Vivian Bykerk 11 , Janet E. Pope 12 and CATCH Investigators 13 ,
1
University of Western Ontario, London, ON, 2 McMaster
University, Hamilton, ON, 3 Schulich School of Medicine and
Dentistry, London, ON, 4 Southlake Regional Health Centre,
Newmarket, Newmarket, ON, 5 Institut de Rhumatologie,
Montreal, QC, 6 CHUS - Sherbrooke University, Sherbrooke,
QC, 7 University of Manitoba, Winnipeg, MB, 8 St. Joseph’s
Hospital, London, ON, 9 St. Josephs Health Ctr, London, ON,
10
University of Toronto, Toronto, ON, 11 Brigham & Women’s
Hospital, Boston, MA, 12 St. Joseph’s Health Care, University
of Western Ontario, London, ON, 13 Toronto, ON
2203. Better Retention Rate of Rituximab Vs Anti-Tnf Agents
As Second Line therapy in RA Patients Failing a First
Anti-Tnf Agents: Results From the Rhumadata® Registry.
D. Choquette, Institute of Rheumatology of Montreal,
Montreal, QC
2204. Effect of Tocilizumab on Hematologic Markers Implicates
Interleukin-6 Signaling in the Anemia of Rheumatoid
Arthritis. John D. Isaacs 1 , Olivier Harari 2 , Uwe Kobold 3 ,
C. Bernasconi 4 and Janet S. Lee 5 , 1 Newcastle University,
Newcastle Upon Tyne, United Kingdom, 2 Roche, Welwyn,
United Kingdom, 3 Roche Diagnostics GmbH, Penzberg,
Germany, Germany, 4 Roche, Basel, Switzerland, 5 Roche,
Nutley, NJ
2205. Comparison of Disease Characteristics of rheumatoid
arthritis patients in Remission According to the DAS
Criteria Versus the New ACR/EULAR Criteria in a Real-
World Patient Population. Denis Choquette 1 , William
G. Bensen 2 , Maqbool K. Sheriff 3 , John T. Kelsall 4 , Milton
F. Baker 5 , John S. Sampalis 6 , Susan M. Otawa 7 and Heidi
Imhoff 7 , 1 University of Montreal Hospital Research Centre
(CRCHUM), Notre Dame Hospital Montreal, Montreal,
QC, 2 McMaster University, Hamilton, ON, Hamilton, ON,
3
Nanaimo Regional General Hospital, Nanaimo, BC, 4 Mary
Pack Arthritis Centre, Vancouver, Vancouver, BC, 5 University
of Victoria, Victoria, BC, 6 McGill University & JSS Medical
Research, Montreal, QC, 7 Merck Canada Inc, Kirkland, QC
2206. Golimumab Treatment Inhibits Progression in Joint
Damage in Patients with Psoriatic Arthritis Regardless of
Baseline Disease Severity. Arthur Kavanaugh 1 , Dafna D.
Gladman 2 , Anna Beutler 3 , Chenglong Han 4 and GO-REVEAL
Clinical Investigators, 1 University of California San Diego,
San Diego, CA, 2 University of Toronto, Toronto Western
Hospital, Toronto, ON, 3 Centocor R&D, a division of Johnson
& Johnson Pharmaceutical Research & Development, LLC,
Malvern, PA, 4 Johnson & Johnson Pharmaceutical Services,
LLC, Malvern, PA